predisposes to the development of desmoid tumors. 5, 6 Several risk factors for recurrence after surgery have been described. A recent literature survey indicated that young age and positive surgical margins are prognostic for recurrence in multivariate analysis. Tumor size was prognostic in 2 of the 4 studies testing size in multivariate analysis. 7 In a meta-analysis of 1295 patients with surgically treated extra-abdominal desmoid tumors, a positive resection margin was associated with a higher recurrence rate. Adjuvant radiotherapy after surgery with positive margins decreased the recurrence rate. 8 Another multivariate analysis of 495 patients also identified extremity location but not surgical margin as a prognostic factor for recurrence. 9 High Ki67 and cyclin A are associated with a poor prognosis in breast cancer, prostate carcinomas, and soft-tissue sarcomas. [10] [11] [12] However, the role of proliferation in desmoid tumors has not been clearly defined. Ki67 expression in desmoid tumors has been assessed using various techniques and cut-off points, with inconsistent results. To our knowledge, cyclin A expression has not been evaluated in desmoid tumors. This work aims to assess the prognostic value and association of Ki67 and cyclin A by immunohistochemistry with clinicopathological parameters in desmoid tumors.
| MATERIAL AND METHODS

| Patients
The study included 90 patients with desmoid tumors referred to Helsinki University Hospital between 1987 and 2011. Clinical data were retrieved from patient charts and databases. An experienced sarcoma pathologist (MR) re-evaluated the diagnostic specimens.
Patients lacking clinical data or follow-up were excluded, as was one patient with an incorrect diagnosis on review. The study was approved by the Ethics Committee of Helsinki University Hospital (270/13/03/00/2011) and the National Supervisory Authority for
Welfare and Health. The study was conducted in accordance with the Helsinki Declaration.
| Tissue arrays and immunohistochemistry
The tissue micro array (TMA) was generated from formalin-fixed paraffin-embedded surgical specimens. The pathologist (MR) selected the representative tumor areas for punching, and 3 or more 1 mm punches were obtained from each tumor. Punching was carried out using a manual microarrayer (BeecherInstruments Inc, Silver Spring, MD). Three parallel tissue array blocks were created.
Tissue array blocks were cut into 4 μm thick sections and subsequently deparaffinized with xylene and rehydrated with graded concentrations of ethanol. Antigen retrieval was performed in Tris-EDTA buffer (pH 9) in the pretreatment module by heating sections.
Immunostainings were carried out with mouse monoclonal cyclin A 
| Immunostainings
The TMA slides were digitalized using the Pannoramic 250® digital inclusion. All specimens with ≥300 neoplastic nuclei were included for analysis. If more than one specimen was acceptable per patient, the one with the highest proliferation rate was chosen out of core biopsies with >500 tumor cells. In cores with 300-500 tumor cells, the specimen with the highest tumor cell number was selected.
Nuclear β-catenin was immunohistochemically examined and found to be expressed in all tumors.
| Statistical analysis
The Determination of optimal cyclin A and Ki67 cut-off values was done by partitioning the patient material at 10% steps from the 10th to the 90th percentile and calculating the hazard ratio, confidence intervals, and P-value at each step.
| RESULTS
Cyclin A and Ki67 were assessable in 74 and 70 of 90 patients, respectively. Fourteen patients were not evaluable for cyclin A or SANTTI ET AL.
| 193
Ki67 due to failed staining or low cell number, and were excluded.
The median follow-up was 11 years (range from 0.1 to 29 years).
Patient and treatment characteristics are shown in Table 1 .
| Expression of cyclin A and Ki67
Cyclin A immunopositivity varied from 0% to 9.9%, with a median of 1.5% and a mean of 1.9%. Ki67 immunopositivity varied from 0.3% to 13.8%, with a median of 3.9% and a mean of 4.6%
( Figure 1 ). Both cyclin A and Ki67 immunostainings were detected only in tumor cell nuclei. Cyclin A significantly correlated with Ki67 (r p = .79, P < .001).
| Associations between clinical characteristics and immunohistochemical expression of cyclin A and Ki67
Associations between cyclin A and clinical characteristics are listed in 
| Prognosis
Cox univariate analysis showed that positive surgical margin (HR 5.2, 95% CI = 1.6-16.2, P = .005), extremity location (HR 5.0, 95% CI = 2.0-12.5, P = .001), high cyclin A expression (HR = 1.3, 95% CI = 1.0-1.5, P = .02), and sex (HR 2.6, 95% CI = 1.1-6.2, P = .03) were associated with RFS (Table 2 ). Ki67 had no significant prognostic impact. In multivariate analysis, extremity location (HR 5.3, 95% CI = 1.7-16.8, P = .005), positive surgical margin (HR 6.0, 95% CI = 1.6-22.5, P = .008), and high cyclin A expression (HR 1.9, 95% CI = 1.1-3.2, P = .02) were independent prognostic variables ( Table 2 ). Multivariate analyzes including only two factors retained the significance for cyclin A in models including either surgical margin (P = .005) or location (P = .01).
All 9 alternative cut-offs indicated a higher risk of progression with high cyclin A values; however, the cut-offs at the 70-90 percentiles SANTTI ET AL. yielded the most consistent and significant association with prognosis (Table 3 ). The lowest cut-off at 0.72% displayed a very high hazard rate for progression, but the confidence levels were extremely wide due to only one recurrence in the low proliferation group. RFS according to cyclin A levels at the 80% percentile cut-off at 2.98%
showed a hazard rate of 3.5 (P = .006) and is shown in Figure 2 . None of the nine alternative cut-off values for Ki67 yielded any significant association with RFS. HR varied between 0.9 and 2.3, with the highest HR (2.3) at the 70th percentile (5.99%), with a P-value of .07 (Supporting Information Table 1 ).
| DISCUSSION
In the present study, high cyclin A was significantly associated with postoperative RFS in desmoid tumors, whereas Ki67 showed only a nonsignificant trend toward being prognostic. Proliferation biomarkers have not previously been extensively studied in desmoid tumors. To our knowledge, cyclin A expression has not been investigated before in desmoid tumors, whereas only a few studies have investigated the prognostic impact of Ki67, with conflicting results. Ki67 is an established prognostic and predictive tool in various cancer types, such as breast cancer, soft-tissue sarcomas, and neuroendocrine neoplasms, and it is probably the most extensively studied proliferation marker.
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Expression of Ki67 and cyclin A was low compared with malignant mesenchymal tumors. The median Ki67 index was 3.9%
(mean 4.6%) and the median percentage of cyclin A positive nuclei was 1.5% (mean 1.9%). In a previous study of sarcomas by our group, the corresponding values were 18% and 11%, respectively. 11, 16 In another series of 193 patients with soft-tissue sarcomas of the trunk and extremities, the median Ki67 index was 30%. 17 Furthermore, in 216 patients with nonvisceral soft-tissue sarcoma, the median Ki67 index was 12%. 18 In desmoid tumors, previously published data on Ki67 expression agree with the present study in that proliferation is low, with mean Ki67 rates ranging from unmeasurable to 8.7%. [19] [20] [21] [22] [23] [24] Visual analysis in four studies with 38, 15, 31, and 51 patients yielded mean Ki67
proportions of 3.0%, 3.2%, 8.7%, and 1.9%, respectively. [21] [22] [23] 25 Digital Ki67 scoring in a study of 42 patients with desmoid tumors yielded a mean rate of 6%, 24 whereas another study of 80 patients reported a mean value of 8.1%, with the highest scores in extraabdominal tumors. 20 In some publications without explicit numerical values, Ki67 was stated to be positive from 3% to 38% of tumors, with various cut-off values from 2% to 5%, [26] [27] [28] whereas others only briefly mentioned that proliferation was low. 29, 30 Three previous studies have evaluated Ki67 as a prognostic biomarker in desmoid tumors. 23, 31, 32 One of these, however, studied a mixture of sarcomas and desmoid tumors and separate results from desmoid tumors were not reported. 31 One of the remaining studies with 33 patients with desmoid tumors reported an association with high Ki67 and short disease-free survival, whereas Ki67 was not prognostic in the other study (n = 51). 23, 32 Despite the fact that Ki67 and cyclin A were significantly correlated in the present study, high Ki67 labeling was only weakly and non-significantly prognostic in contrast to cyclin A.
Overexpression of cyclin A has been reported to be an unfavorable prognostic indicator in soft-tissue sarcomas and in breast cancer, but has not, to our knowledge, been reported in desmoid tumors. 10, 11, 33 Cyclin A regulates the cell cycle progression in S and G2 phases, whereas Ki67 is present in all the cell cycle phases besides the resting phase G0. Hypothetically, the more T A B L E 3 Cox univariate analysis of cyclin A expression divided from 10th to 90th percentiles and recurrence-free survival 
| CONCLUSIONS
Cyclin A overexpression is an independent prognostic factor of relapse in desmoid tumors after resection.
